Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.
UMR-CNRS 5510 Matéis, Villeurbanne, INSA de Lyon, Université Claude Bernard Lyon 1, University of Lyon, Lyon, France.
Eye (Lond). 2021 Aug;35(8):2119-2135. doi: 10.1038/s41433-021-01487-0. Epub 2021 Apr 1.
Current guidelines on the management of patients with neovascular age-related macular degeneration (nAMD) lack clear recommendations on the interpretation of fluid as seen on optical coherence tomography (OCT) imaging and the incorporation of this information into an ongoing disease treatment strategy. Our objective was to review current guidelines and scientific evidence on the role of fluid as a biomarker in the management of nAMD, and develop a clinically oriented, practical algorithm for diagnosis and management based on a consensus of expert European retinal specialists. PubMed was searched for articles published since 2006 relating to the role of fluid in nAMD. A total of 654 publications were screened for relevance and 66 publications were included for review. Of these, 14 were treatment guidelines, consensus statements and systematic reviews or meta-analyses, in which OCT was consistently recommended as an important tool in the initial diagnosis and ongoing management of nAMD. However, few guidelines distinguished between types of fluid when providing recommendations. A total of 52 publications reported primary evidence from clinical trials, studies, and chart reviews. Observations from these were sometimes inconsistent, but trends were observed with regard to features reported as being predictive of visual outcomes. Based on these findings, diagnostic recommendations and a treatment algorithm based on a treat-and-extend (T&E) regimen were developed. These provide guidance on the diagnosis of nAMD as well as a simple treatment pathway based on the T&E regimen, with treatment decisions made according to the observations of fluid as a critical biomarker for disease activity.
目前关于新生血管性年龄相关性黄斑变性(nAMD)患者管理的指南缺乏对光学相干断层扫描(OCT)成像中所见液体的解释以及将该信息纳入正在进行的疾病治疗策略的明确建议。我们的目的是回顾关于液体作为 nAMD 管理中的生物标志物的作用的当前指南和科学证据,并基于欧洲视网膜专家的共识制定一种针对诊断和管理的临床导向、实用算法。在 2006 年以后发表的与 nAMD 液体作用相关的文章,我们在 PubMed 上进行了检索。共筛选出 654 篇相关文献,并纳入 66 篇文献进行综述。其中,有 14 篇是治疗指南、共识声明和系统评价或荟萃分析,这些都一致推荐 OCT 是 nAMD 初始诊断和持续管理的重要工具。然而,在提供建议时,几乎没有指南对液体类型进行区分。共有 52 篇出版物报告了来自临床试验、研究和图表回顾的主要证据。这些观察结果有时并不一致,但在报告的对视觉结局有预测作用的特征方面观察到了一些趋势。基于这些发现,制定了诊断建议和基于治疗和扩展(T&E)方案的治疗算法。这些为 nAMD 的诊断提供了指导,以及基于 T&E 方案的简单治疗途径,根据液体作为疾病活动的关键生物标志物的观察结果来做出治疗决策。